Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humanigen, Inc. - Common Stock (NQ: HGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humanigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
From Humanigen, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
20 Stocks Moving in Monday's Pre-Market Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-... 
Via Benzinga
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
From Humanigen, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
Humanigen to Present at Investor Conferences January 7 and 13, 2022
From Humanigen, Inc.
Via Business Wire
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
From Humanigen, Inc.
Via Business Wire
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
Humanigen, Inc. (NASDAQ:HGEN) Investor Notice: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 12/13/2021 -- Certain directors of Humanigen, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Exposures COVID-19 Product Safety
After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News
Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19... 
Via Benzinga
Exposures COVID-19 Product Safety
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)... 
Via Benzinga
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
From Humanigen, Inc.
Via Business Wire
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
From Humanigen, Inc.
Via Business Wire
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results... 
Via Benzinga
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
From Humanigen, Inc.
Via Business Wire
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
From Humanigen, Inc.
Via Business Wire
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
From Humanigen, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Autolus Therapeutics (NASDAQ:AUTL) stock rose 21.04% to $6.73 during Monday's pre-market session. The company's market cap stands at $490.7 million. As per... 
Via Benzinga
Humanigen Announces Release of Abstracts at ASH
From Humanigen, Inc.
Via Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in November
From Humanigen, Inc.
Via Business Wire
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
From Humanigen, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS